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Abstract The objective of this study was to analyse
sociodemographic differences in medication use, health-
care contacts and sickness absence among individuals with
medication-overuse headache (MOH). A cross-sectional,
population survey was conducted, in which 44,300 Swedes
(C15 years old) were interviewed over telephone. In total,
799 individuals had MOH. Of these, 47 % (n = 370) only
used over-the-counter medications. During the last year,
46 % (n = 343) had made a headache-related visit to their
physician and 14 % (n = 102) had visited a neurologist.
Among individuals aged \30 years, the number of days/
month with headache was greater than the number of days
with medication use, whereas the opposite was true for
those C30 years. Both the proportion using prophylactic
medication and the proportion having consulted a neurol-
ogist were smaller among those who only had elementary
school education than among those with higher education
(p = 0.021 and p = 0.046). Those with a lower level of
education also had a higher number of days/month with
headache and with medication use than those with a higher
educational level (p = 0.011 and p = 0.018). The MOH-
sufferers have limited contacts with health-care and pre-
ventive measures thus need to include other actors as well.
Particular efforts should be directed towards those with low
educational levels, and more research on medication use in
relation to age is required.
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Introduction
Paradoxically, medications that normally relieve headache
may also increase the frequency of headache if overused,
causing so-called medication-overuse headache (MOH)
[1]. Medication-overuse headache develops in individuals
with primary headache disorders who overuse acute
headache medication [2]. The MOH-sufferers have a
headache at least 15 days/month and the disorder has a
considerable impact on their quality of life [2–5].
In order to manage their situation, individuals with
MOH use large quantities of medications, by deﬁnition
triptans, ergots, opioids, or combination analgesics on at
least 10 days/month or simple analgesics at least 15 days/
month [2]. Addictive behaviour has been discussed in
relation to MOH, particularly among those overusing
psychotropic substances, and it has been suggested that
such users should be regarded as a speciﬁc, more severe
subgroup of MOH [6–8]. The MOH is one of the forms of
headache that most frequently causes patients to seek care
at headache centres [9–11]. Around 30 % of patients seen
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headache sufferers never seek medical care and many of
those who do, do not return for follow-up visits [12, 13].
The MOH-sufferers also report more sickness absence and
more days with reduced productivity at work than migra-
ineurs [14].
In previous studies on MOH, little attention has been
paid to sociodemographic differences. The prevalence of
the disorder is 1–2 % in the general population and it is
known that it is more prevalent among women than men,
that there are age-differences in prevalence, and that it is
more common among those with a low socioeconomic
status [4, 15–17]. However, no studies have looked more
closely at these differences in relation to medication use,
health-care contacts and sickness absence. Such knowledge
is important in order to shed light on how resource use is
distributed and to identify groups for possible future
interventions. In addition many studies, particularly those
regarding health-care contacts [9–11], are based on clinical
samples, and there is thus a need for population-based
studies in this area. The aim of this study was therefore to
analyse sociodemographic differences in medication use,
health-care contacts and sickness absence among individ-
uals with MOH. These factors were analysed from a pop-
ulation perspective in Sweden.
Methods
Sampling and interview
Data were collected through a national telephonic survey
conducted by Sifo Research International, a Swedish
opinion poll agency. This survey has an omnibus design. It
runs continuously, reaches approximately 1,000 individuals
per week and provides a means for data collection for
different research projects, companies, and organisations.
Sampling for this study was performed between March
2009 and March 2010 and consisted of randomised sam-
pling in two steps. In the ﬁrst step, a household was
selected and in the second step, a household member from
that speciﬁc household was singled out. The basis for
selection was the current national telephone directory.
Households without telephones were not included. A com-
puter programme randomly chose numbers in the telephone
directory. It also constructed new telephone numbers by
adding digits to those already chosen. This procedure
ensured inclusion of numbers that were not listed in the
directory. If the number led to a company or a public
authority, or if there was an unobtainable tone, a new
number was chosen. Numbers with no reply were called
again later and if there was still no reply, they were
replaced by new numbers. When the interviewer came into
contact with a household, he or she initially collected
information on the number of Swedish-speaking household
members aged C15 years, and the computer programme
randomly chose one of these individuals for the interview.
A large group of lay interviewers aged C18 years, with
an average of 2 years of interviewing experience, admin-
istered the questionnaire. They introduced the interview by
explaining that it was a survey by Sifo, covering several
different areas, which would last approximately 5–25 min.
Verbal informed consent was obtained and all had the right
to decline participation or to refuse to answer speciﬁc
questions without explanation. The study protocol was
approved by the Regional Ethical Review Board in
Gothenburg.
Questionnaire
All respondents were asked background questions con-
cerning sex, age, and the highest level of education (ele-
mentary school, high school or university). The
interviewers introduced the part of the survey related to this
study by explaining that the questions concerned headache
and came from the University of Gothenburg. This part of
the survey began with two screening questions and only
respondents who passed these were asked further questions.
In order to pass, the respondent would have to report
headache present on C15 days/month and medication use
for C10 days/month during the past 3 months.
The subsequent interview comprised questions about
medication use, health-care contacts, headache-related
sickness absence and primary headache.
Medication use: The respondents were ﬁrst asked to
name the medication that they most frequently used in
order to treat their headache (primary acute medication).
They were then asked a series of follow-up questions
regarding this medication: frequency of use, form of dos-
age and whether they bought it on prescription, as over-the-
counter (OTC)-medication or both (this variable was
dichotomised into ‘‘always OTC’’ and ‘‘sometimes or
always on prescription’’). For medications other than the
primary one, only the name and the frequency of use were
asked for. The medications reported were divided into ﬁve
different groups corresponding to the diagnostic criteria of
MOH [2]. Addictive behaviour has been discussed in
relation to MOH [6–8]. Therefore, in some analyses all
medications containing psychotropic substances (alone or
in combination with other active compounds) were ana-
lysed as one group. There was also a question regarding the
use of prophylactic medication.
Health-care contacts: The respondents were asked how
many times they had visited a physician due to headache
during the last year. They were also asked what type of
physician they had visited (neurologist or other), number of
282 J Headache Pain (2012) 13:281–290
123prescribing physicians and whether any physician had ever
informed them that excessive use of acute headache med-
ication could lead to an increased frequency of headache.
Sickness absence: Sickness absence was reported as
mean number of days/month and person during the last
3 months and only analysed among those aged 18–65 years.
Headache diagnoses: The 2006 International Headache
Society appendix criteria were used to diagnose MOH and
the primary headaches were diagnosed as ‘‘migraine’’ or
‘‘other headaches’’ according to the International Classiﬁ-
cation of Headache Disorders second edition (ICHD-II) [2,
18].
Statistical analysis
The IBM SPSS Statistics version 19.0 for Windows was
used for all statistical analyses. Differences between per-
centages were analysed using the Pearson Chi square test.
All percentages are valid percentages, i.e. calculated after
the exclusion of missing values. Means are presented with
standard deviation (SD). Differences between means were
tested using the independent sample t test. When three or
more means were compared, univariate analysis of vari-
ance (ANOVA) was used. When a difference was detected,
the most appropriate post hoc range test was performed
to determine which scores differed. Associations were
investigated using univariate logistic regression when
the dependent variable was dichotomous and Pearson
correlation for continuous variables. The signiﬁcance level
was set to p\0.05.
Results
The sample
In total, 44,300 individuals (24,195 women and 20,105
men) were interviewed. Sampling was performed by the
method of substitution (the interviewer called a new
number if there was no reply) and the total number of
telephone calls was not documented. The drop-out rate,
deﬁned as individuals who agreed to answer the overall
interview but who declined to answer the section regarding
headache and medication use, was 1.6 % (n = 700). A
total of 799 individuals with MOH were identiﬁed. Of
these, 76 % (n = 609) were women and the mean age was
51 years (SD ± 15). The demographic characteristics of
the sample are presented in Table 1.
The mean frequency of headache was 22.8 days/month,
and 35 % (n = 276) reported having a headache every day.
Men reported a higher frequency than women (23.7 vs.
22.6 days/month, p = 0.033) and those who had only
had elementary school education reported a higher fre-
quency (23.8 days/month) than those who had attended
high school (22.4 days/month, p = 0.011) or university
(21.9 days/month, p = 0.0021).
Table 1 Population
characteristics among 799
individuals with medication-
overuse headache (MOH)
Men (n) Women (n) Total
n %
Total 190 609 799 100
Age (years)
15–20 2 21 23 2.9
21–29 5 41 46 5.8
30–39 22 92 114 14.3
40–49 44 148 192 24.0
50–64 72 212 284 35.5
65–74 27 62 89 11.1
C75 17 33 50 6.3
Missing 1 0 1 –
Educational level
Elementary school 86 210 296 37.3
High school 70 245 315 39.7
University 32 150 182 23.0
Missing 2 4 6 –
Primary headache
Migraine 78 316 394 58.5
Other headaches 76 204 280 41.5
Missing 36 89 125 –
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Daily medication use was reported by 46 % (n = 366) and,
on average, the participants reported using acute medica-
tion 23.5 days/month. The frequency was lowest among
the young and higher in older age groups (r = 0.18,
p\0.001). Among the youngest, the number of days/
month with headache was greater than the number of days/
month with medication use, whereas the opposite was true
for those aged C30 years (Fig. 1). The mean number of
days/month of medication use was higher among those who
had only attended elementary school (24.4 days/month)
than among those with high school education (23.0 days/
month, p = 0.018).
More than half (53 %, n = 423) reported having used at
least two different acute medications during the last
3 months, and the mean was 1.8 different acute medica-
tions (SD ± 0.9). Simple analgesics were most often the
primarily used acute medication and opioids were more
common among men than women (p = 0.018) (Table 2).
The majority reported taking the primary acute medication
orally (n = 754, 96 %), and use of prophylactic medication
was reported by 11 % (n = 83) (Table 3). The proportion
using prophylactics was smaller among those who only had
elementary school education compared to those with uni-
versity education (p = 0.021).
Almost half (47 %, n = 370) reported only using OTC
medications (Table 3). This proportion was higher among
the young than the old (p\0.001, OR 0.98, 95 % CI
0.97–0.98) and lower among those who had only attended
elementary school compared to those with high
school education (p = 0.0032) or university education
(p = 0.0081). Among those who used prescription medi-
cation, 82 % (n = 311) reported receiving all prescriptions
from the same physician. This proportion did not differ
according to the primary medication, e.g. between those
using psychotropics (n = 64, 81 %) and those using other
medications (n = 246, 82 %) (p = 0.78).
Thirty-two individuals reported using an opioid as the
primary acute medication and 51 used a combination
analgesic containing opioids. Thus, 10 % (n = 83) used a
psychotropic medication as primary acute medication. The
proportion was higher among men (16 %, n = 31) than
women (8.5 %, n = 52) (p = 0.0022). Both the frequen-
cies of headache and of medication use were higher among
those using psychotropics (25.5 days/month, SD ± 5.9 and
27.1 days/month, SD ± 5.2, respectively) than among
those using other medications (22.5 days/month, SD ± 6.2
and 23.1 days/month, SD ± 6.8) (p\0.001 in both
cases). Those using psychotropic medications were older
(mean age 55 years, SD ± 14) than those using other
medications (mean age 51 years, SD ± 15) (p = 0.011)
and had made more visits to their physician (p = 0.0040)
(Table 4).
Fig. 1 Frequency of headache and of medication use in relation to
age, among 799 individuals with medication-overuse headache
(MOH). The frequencies are reported as the mean number of days/
month over the last 3 months
Table 2 Primary overused medication, reported by 785 individuals with medication-overuse headache (MOH)
Type of medication Men Women Total Age of user (years) Frequency of use (days/month)
e
n % n % n % Mean SD mean SD
Triptan 10 5.5 55 9.0 65 8.3 49.9 12.4 21.7
b 7.0
Ergotamine 2 1.1 5 0.8 7 0.9 59.3 15.0 21.1 9.1
Opioid 13 7.1
a 19 3.2
a 32 4.1 55.0 14.2 27.5
b,c,d 4.9
Combination analgesic 48 26.2 125 20.8 173 22.0 51.7 13.0 23.9
c 6.9
Simple analgesic 110 60.1 398 66.1 508 64.7 50.4 16.0 23.4
d 6.7
Total 183 100 602 100 785 100 50.9 15.1 23.3 6.8
Values marked with the same letter are signiﬁcantly different from each other (Pearson Chi square test and ANOVA with post hoc test Tukey’s
HSD were used) (
ap = 0.018,
bp = 0.0010,
cp = 0.041,
dp = 0.0063)
e Frequency of medication use was reported as the mean number of days/month over the last 3 months
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On average, the participants had made 1.7 visits to their
physician due to headache during the last year (SD ± 3.8,
range 0–52) (Table 4). In the same period, less than half
(46 %, n = 343) had visited their physician at all and 14 %
(n = 102) had seen a neurologist. The proportion was
lower among those who had only attended elementary
school than among those who had a high school education
(p = 0.046). Less than half (46 %, n = 362) reported ever
having received information about MOH from a physician
(Table 4). This proportion was larger among those who
used prescription medications compared to those who only
used OTC medications (p\0.001), and those who had
received information had made more physician visits (2.3
visits) than those who had not been informed (1.1 visits)
(p\0.001).
Sickness absence
The majority (n = 354, 79 %) of those in the working age
group (18–64 years, n = 446) reported no headache-rela-
ted sickness absence at all during the last 3 months
(Table 5). Among the 92 who did, the mean was 14.7 days/
month, being higher among men than women (p = 0.032).
The proportion with headache-related sickness absence was
higher in the youngest age group (18–20 years, 54 %) than
in all other age groups and higher in the group who used
psychotropic medications compared to those using other
medications (p\0.001) (Table 5).
Discussion
This is the ﬁrst population-based study of medication use,
health-care contacts and sickness absence among MOH-
sufferers. We found that almost half only used OTC
medications, that less than half had made a headache-
related visit to their physician during the last year and that
only 14 % had consulted a neurologist during the corre-
sponding period. Those using psychotropic medications
seemed to suffer from a greater disease burden than those
using other medications. There were several important
sociodemographic differences. Men with MOH reported a
higher frequency of headache than women and older
MOH-sufferers medicated more frequently than younger
individuals. Both the use of medications and health-care
differed in relation to educational level.
Table 3 Medication use among
individuals with medication-
overuse headache (MOH),
illustrated by the proportions
using over-the-counter (OTC)
acute medications and
prophylactic medication
Values marked with the same
letter are signiﬁcantly different
from each other (Pearson Chi
square test was used):
ap 0.027,
bp = 0.0068,
cp = 0.0010,
dp\0.001,
ep\0.001,
fp = 0.039,
gp = 0.0061;
hp\0.001,
ip =\0.001,
jp =\0.001,
kp = 0.023,
lp = 0.031,
mp = 0.0032,
np = 0.0081,
op = 0.010,
pp = 0.021,
qp = 0.0032)
Parameter Total (n) Proportion only buying OTC
(n = 785)
Proportion using prophylactics
(n = 782)
n % n %
Total 799 370 47.1 83 10.6
Sex
Men 190 83 45.6 22 12.0
Women 609 287 47.6 61 10.2
Age (years)
15–20 23 18 78.3
a,b,c 0 0.0
21–29 46 32 71.1
f,g,h,i,j 5 10.9
30–39 114 59 53.2
a,f,k,l 14 12.5
40–49 192 92 48.4
b,g 22 11.7
50–64 284 119 42.8
c,h 28 10.1
65–74 89 33 37.1
d,i,k 8 9.3
C75 50 17 34.7
e,j,l 5 10.2
Missing 1 0 – 1 –
Education
Elementary school 296 114 39.4
m,n 22 7.7
p
High school 315 160 51.4
m 35 11.2
University 182 93 52.0
n 26 14.4
p
Missing 6 3 – 0 –
Primary headache
Migraine 394 167 43.2
o 53 13.6
q
Other headache 280 148 52.9
o 18 6.4
q
Missing 125 55 – 12 –
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absence
We found that 44 % had made a headache-related visit to
the physician during the last year. Previous population-
based ﬁgures in MOH are lacking but the ﬁnding is in line
with that found in a study of chronic daily headache
(CDH), in which Scher et al. [19] reported a corresponding
ﬁgure of 46 %. Only 14 % of our participants had con-
sulted a neurologist during the last year and less than half
could remember ever having been informed about MOH by
a physician. This proportion was larger among those who
used prescription medications than among those only using
OTC medications, but then it is important to consider that
almost half of the participants reported only using OTC
medications. These ﬁndings suggest that many MOH-suf-
ferers do not have regular contact with health-care pro-
viders. We ﬁnd this remarkable considering the disease
burden that is indicated by the reported frequencies of
headache and medication use. A previous Swedish popu-
lation-based study on migraine showed that 73 % had
stopped seeing or had never seen a physician for their
Table 4 Health-care contacts among 799 individuals with medication-overuse headache
Parameter Total (n) Number of visits to the
physician last year (n = 746)
Proportion who had seen a neurologist
during last year (n = 746)
Proportion who had been
informed about MOH (n = 785)
Mean SD n % n %
Total 799 1.7 3.8 102 13.7 362 46.1
Sex
Men 190 2.0 4.1 25 13.2 79 43.4
Women 609 1.6 3.6 77 12.6 283 46.9
Age (years)
15–20 23 2.4 4.8 3 13.0 8 34.8
21–29 46 1.7 3.7 9 19.6 13 28.3
30–39 114 1.9 3.5 14 12.3 55 49.5
40–49 192 1.9 4.8 23 12.0 80 42.1
50–64 284 1.5 3.2 42 14.8 151 54.3
65–74 89 1.7 3.9 7 7.9 37 42.0
C75 50 1.1 2.0 4 8.0 17 35.4
Missing 1 – – 0 – 1 –
Educational level
Elementary school 296 1.8 3.7 30 10.1
d 131 45.5
High school 315 1.6 3.0 48 15.2
d 143 45.8
University 182 1.7 5.1 23 12.6 88 49.2
Missing 6 – – 1 – 0 –
Primary headache
Migraine 394 2.0
a 4.5 55 14.0 205 52.7
f
Other headaches 280 1.3
a 2.8 35 12.5 101 36.1
f
Missing 125 – – 12 – 56 –
Prescription status
On prescription 415 2.6
b 4.7 85 20.5
e 228 55.6
f
Always OTC 370 0.7
b 1.9 16 4.3
e 131 35.4
f
Missing 14 – – 1 – 3 –
Primary acute medication
Psychotropic 83 3.2
c 4.8 21 25.3 54 65.9
g
Not psychotropic 716 1.5
c 3.6 81 11.3 308 43.8
g
Type of physician
Neurologist 102 4.0 4.2 99 66 64.7
Other physician 241 3.1 3.2 99 132 55.5
OTC over the counter
Values marked with the same letter are signiﬁcantly different from each other (t tests and Pearson Chi square tests were used):
ap = 0.021,
bp\0.001,
cp = 0.0040,
dp = 0.046,
ep\0.001,
fp\0.001,
gp\0.001
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consultation rates may be found in a qualitative study of
migraine and CDH by Peters et al. [20]. They reported that
some patients had low expectations and that they ques-
tioned the physicians’ ability and interest to treat headaches
to the extent that they chose not to consult for headaches
[20]. The ﬁndings may also be a result of limited access to
headache care. We believe that it is crucial to encourage
increased contact between headache sufferers and health-
care, and that in order to reach this patient group, pre-
ventive work should include other actors, such as
pharmacies and other traders that sell OTC medications.
One in ten participants reported using a psychotropic
medication as the primary acute medication. Colas et al. [4]
found a corresponding ﬁgure of 12.5 % in their population-
based study. In the present study we found several differ-
ences between those using psychotropics and those who did
not, e.g. the frequencies of headache and of medication use,
the proportion with headache-related sickness absence and
the number of physician visits were all higher among the
former. The higher consultation rate may partly be
explained by the fact that no psychotropic medications are
available without prescription in Sweden. The differences
suggest that MOH-sufferers using psychotropic medica-
tions are more bothered by their disorder than those using
other medications. Since this was a cross-sectional study,
causality is unknown. The ﬁndings may, however, be
interpreted as support for the suggestion that MOH-suffer-
ers who overuse psychotropic substances should be regar-
ded as a speciﬁc, more severe subgroup of MOH [6–8].
One-ﬁfth of the participants reported headache-related
sickness absence. This proportion could be regarded as
small given that more than one-third reported having daily
headaches. However, the ﬁnding may partly be explained
by results reported by Ferrari et al. [21], who found that
more than half of those with headache reported taking an
analgesic and continuing working if the headache came
during the working day. Among the 20 % who did report
sickness absence in our study, the mean monthly frequency
was as high as 15 days/person. Sickness absence thus seems
to be skewed in the sense that only a small proportion
reported headache-related sickness absence, but within this
proportion the rate of sickness absence was high.
Sociodemographic differences
Men with MOH reported a higher frequency of headache
than women. To our knowledge, this difference has not
been reported previously and contrasts with what is usually
reported for the primary headaches [22]. Interestingly,
Table 5 Headache-related
sickness absence among those
of working age (18–64 years)
with MOH (n = 446)
Values marked with the same
letter are signiﬁcantly different
from each other (Pearson Chi
squares test and t tests were
used): (
ap = 0.0084,
bp = 0.027,
cp = 0.017,
dp\0.001,
ep = 0.048,
fp = 0.030,
gp = 0.0033,
hp\0.001,
ip = 0.032)
Parameter Total (n) Proportion with sickness
absence C1 day
Sickness absence among those with
C1 day (days/month)
n % Mean SD
Total 446 92 20.6 14.7 13.1
Sex
Men 92 20 21.7 20.2
i 13.0
Women 354 72 20.3 13.3
i 12.8
Age (years)
18–20 13 7 53.8
a,b,c,d 9.9 9.8
21–29 41 7 17.1
a 19.9 5.2
30–39 83 20 24.1
b 11.9 13.4
40–49 145 34 23.4
c,e 15.9 13.0
50–64 164 24 14.6
d,e 15.0 13.7
Educational level
Elementary school 123 23 18.7 18.4 12.8
High school 208 53 25.5
f 14.6 13.3
University 113 16 14.2
f 9.4 11.8
Missing 2 – – – –
Primary headache
Migraine 225 61 27.1
g 13.9 13.0
Other headaches 153 22 14.4
g 17.9 13.2
Missing 68 – – – –
Primary acute medication
Psychotropic 38 17 44.7
h 19.0 13.8
Not psychotropic 408 75 18.4
h 13.7 12.8
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report using acute medications more often than women.
Men also had a higher rate of headache-related sickness
absence than women. Most other studies concerning sick-
ness absence and headache have reported higher ﬁgures
among women [23, 24]. However, the latter ﬁnding could
be a reﬂection of the higher frequency of headache found
among men with MOH in this study. Furthermore, overuse
of psychotropics was more common among men than
women and since sickness absence was associated with the
use of psychotropics, this may have contributed to the sex-
difference in sickness absence.
The frequency of medication use differed with age,
being the lowest among the young, whereas the frequency
of headache did not show the same age pattern. In fact, the
frequency of headache was higher than the frequency of
medication use among the youngest, whereas the opposite
was seen in the older age groups. There was also an
association between older age and a larger proportion using
prescription medications. A similar relation was observed
among migraineurs by Linet et al. [25], who found that the
proportion using prescription medications was almost twice
as high among young men aged 18–29 years than among
boys aged 12–17 years old. Further, the headache-related
sickness absence in our study was surprisingly high among
the youngest. This group was small but the proportion
reporting sickness absence was nevertheless signiﬁcantly
higher than in all other age groups. Since a high rate of
sickness absence is a known risk factor for ending up more
permanently outside the labour market with sickness ben-
eﬁt or social welfare [26], early identiﬁcation of young
individuals with MOH is important. A recent Danish study
showed that medication use for headache follows a
behavioural pattern that may track from adolescence into
adulthood [27], thus further underlining the need for early
identiﬁcation and more research on the strategies used by
young headache sufferers in order to manage headache.
Previous studies have shown that MOH is more pre-
valent among those with a low educational level [15, 17].
In the present study, several signiﬁcant differences relating
to educational level were detected, e.g. both the frequen-
cies of headache and of medication use were higher among
those who only had elementary school education than
among the more highly educated. In a large prospective
study, Hagen et al. [28] showed that low socioeconomic
status was indeed a risk factor for frequent headache, but
this has yet to be conﬁrmed for MOH speciﬁcally. We also
found that those with a lower educational level were less
likely to use prophylactic medication or to have consulted a
neurologist than those with a higher educational level.
These ﬁndings suggest that the use of medications and
health-care is unequal in relation to educational level
among individuals with MOH in Sweden. Such differences
are not in line with the Swedish health-care act, which
states that health-care should be provided to everyone, on
equal terms [29]. There is a need for longitudinal research
in order to evaluate the consequences of these differences
and to analyse whether they are the result of health-care
actually being provided unequally or if help-seeking
behaviours differ in relation to educational level. Similar
differences were recently found in a Swedish study on
epilepsy patients, in which socio-economic characteristics
were important for access to neurologists and the pre-
scriptions of individual antiepileptic medications [30]. The
authors suggested differences in help-seeking behaviour as
a possible explanation.
Methodological considerations
A major methodological strength is the large sample size,
which was based on the entire Swedish population, aged
C15 years. The sample was somewhat skewed towards
containing a larger proportion of women and elderly
compared to the general population but is still considered
representative of the Swedish population, aged C15 years
in 2009. A thorough discussion of the representativeness of
the sample has been published previously [17]. Though the
overall study population is large, there are limited counts in
some of the subgroups. Another potential limitation is that
the interviewers were not headache specialists. However,
in two previous studies comparing structured interviews
conducted by lay interviewers with headache specialist
ratings, the agreement between the two was validated [31,
32]. Both studies used the same diagnostic criteria for
MOH as in the present study [2]. All data in this study are
based on self-report and the risk of recall bias is thus a
potential limitation. However, previous studies comparing
the self-reported use of health-care resources and medica-
tions with registry data have shown high concordance
between the two [33], even when patients were interviewed
over the telephone [34].
Conclusions
The results of this population-based study showed that
many MOH-sufferers have limited contact with health-care
institutions. In order to reach this patient group with pre-
ventive measures, we therefore recommend involving
additional actors, such as pharmacies and other traders that
sell OTC medications. Since we detected several differ-
ences suggesting that the use of medications and health-
care among MOH-sufferers in Sweden is unequal with
regard to educational level, particular effort should be
directed towards those with a low educational level.
Another group that warrants particular effort is MOH-
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123sufferers using psychotropic medications. These individu-
als differed from others in several ways, suggesting that
they suffer from a greater disease burden. Finally, young
individuals with MOH differed from older individuals in
the sense that they medicated less frequently and that they
tended to use OTC medications rather than prescription
medications. Many of these young individuals are most
likely at the beginning of their disease career and more
research on this group and their coping strategies could
shed valuable light on the development from primary
headache to MOH.
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